In:
Science Immunology, American Association for the Advancement of Science (AAAS), Vol. 8, No. 80 ( 2023-02-24)
Abstract:
Most identified tumor-specific antigens are derived from coding regions of the genome that are mutated or overexpressed in tumors, but non-coding regions can also generate MHC-I–presented peptides. Two studies in this issue demonstrate that mRNA splicing events between exons and transposable elements (TEs) can encode immunogenic peptides eliciting T cell responses in human and murine tumors. Merlotti et al . showed that expression of certain exon-TE splicing junctions is tumor-specific in humans and that T cells specific for encoded HLA-I peptides are found in NSCLC patients. In mouse models, Burbage et al . found that immunization with peptides derived from these transcripts slowed tumor growth and that the histone methyltransferase Setdb1 repressed expression of several immunogenic exon-TE splicing junctions. Together, these studies identify exon-TE splicing junctions as a class of immunogenic tumor neo-antigens. See related Research Article by Merlotti et al .—CO
Type of Medium:
Online Resource
ISSN:
2470-9468
DOI:
10.1126/sciimmunol.abm6360
Language:
English
Publisher:
American Association for the Advancement of Science (AAAS)
Publication Date:
2023